文献速递系统性红斑狼疮

GLP-1受体激动剂在系统性红斑狼疮中的应用:范围综述

GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review.
PubMed 文献 · RMD Open · 2026-07-16

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly recognised for benefits beyond glycaemic control, including anti-inflammatory, anti-atherogenic and potential immunomodulatory effects.…

要点

  • GLP-1 RAs在SLE中显示一致的抗炎、代谢及内皮效应,机制涉及降低细胞因子信号、氧化应激和巨噬细胞活化。
  • 当前SLE特异性证据多来自小样本观察性队列、回顾性分析及个案报告,支持性数据多源于临床前研究或外推自其他风湿病。
  • GLP-1 RAs在自身免疫人群中安全性可接受,但两项病例研究报告了药物诱导性狼疮。

核心结论

  • 纳入研究提示GLP-1 RAs可能为SLE提供代谢和抗炎获益,安全性可接受,但SLE特异性临床数据仍有限,需大型高质量前瞻性临床试验细化治疗适应证、最佳患者选择和免疫学效应。

主要发现

  • 机制数据提示GLP-1 RAs可减少细胞因子信号、氧化应激和巨噬细胞活化。
  • 当前SLE特异性证据主要来自小样本观察性队列、回顾性分析和孤立病例报告,支持性抗炎和免疫调节数据多源于临床前研究或外推自更广泛的风湿病人群。
  • GLP-1 RAs在自身免疫人群中安全性可接受,但两项病例研究报告了药物诱导性狼疮。

临床怎么用

  • 对于合并代谢异常或心血管高风险的SLE患者,GLP-1 RAs可能提供代谢和抗炎获益,但需警惕药物诱导性狼疮的可能。
  • 当前证据不足以支持GLP-1 RAs作为SLE的常规治疗,临床决策应个体化并优先考虑参与前瞻性临床试验。

局限性

  • SLE特异性临床数据有限,多来自小样本观察性研究、回顾性分析和病例报告。
  • 支持性抗炎和免疫调节数据多源于临床前研究或外推自其他风湿病人群。
  • 纳入研究包括叙述性综述、机制分析、评论和病例报告,证据等级较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly recognised for benefits beyond glycaemic control, including anti-inflammatory, anti-atherogenic and potential immunomodulatory effects. Given the high burden of metabolic dysfunction, accelerated cardiovascular disease and chronic systemic inflammation in systemic lupus erythematosus (SLE), significant interest has emerged regarding their therapeutic role in this population. METHODS: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided scoping review of PubMed, Embase, Scopus and the Cochrane Library from database inception to April 2026, including peer-reviewed clinical studies, case series, case reports and relevant research evaluating GLP-1 RAs in SLE while excluding conference abstracts and unpublished material. RESULTS: Fourteen studies were included, comprising narrative reviews, mechanistic analyses, editorials and case reports. Across these studies, GLP-1 RAs demonstrated consistent anti-inflammatory, metabolic and endothelial effects relevant to SLE, with mechanistic data suggesting reductions in cytokine signalling, oxidative stress and macrophage activation. Current evidence specific to SLE is largely derived from small observational cohorts, retrospective analyses and isolated case reports, while much of the supportive anti-inflammatory and immunomodulatory data originate from preclinical studies or extrapolated from the broader rheumatic disease populations. GLP-1 RAs appear to have an acceptable safety profile in autoimmune populations, although drug-induced lupus was reported in two case studies. CONCLUSION: Collectively, findings from the included studies suggest that GLP-1 RAs may provide metabolic and anti-inflammatory benefits in SLE with an acceptable safety profile; however, clinical data specific to SLE remain limited and large high-quality prospective clinical trials are required to refine therapeutic indications, optimal patient selection and immunological effects.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sia R, Ting EL, Choy SW, et al. GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review. RMD Open. 2026. PMID: 42463280. doi:10.1136/rmdopen-2026-007037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。